Drug intelligence / Profile preview

OCZ103-OS

Development stage: Approved
Lead developer: Odan Laboratories
Modality: Small Molecules
Administration: Oral

Overview

OCZ103-OS is an investigational drug that has been studied in combination with standard chemotherapy for various cancer indications. It has been evaluated in Phase II clinical trials for unresectable and locally recurrent or metastatic colorectal cancer as a second-line treatment in combination with standard chemotherapy (mFOLFOX6 or FOLFIRI), and for Stage IV non-small cell lung cancer (NSCLC) in combination with platinum-gemcitabine based doublet first-line therapy.

Brand names: Pentam 300Pentam300Pentam-300NebuPent
Other names: pentamidine oralpentamidine isethionate (oral formulation)

Targets

DNA minor grooveS100P (S100 calcium-binding protein P)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on OCZ103-OS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCZ103-OS.

Explore the full profile